Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04301-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Hyunjae Shin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, …. Hauptthemen laut MEDLINE: Cytokine-Induced Killer Cells, Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Most adjuvant therapies for hepatocellular carcinoma (HCC) have failed except for autologous cytokine-induced killer (CIK) therapy, which prolonged recurrence-free survival (RFS) in a previously reported randomized controlled trial (RCT) and real-world data (RWD). METHODS: This study aimed to assess the long-term outcomes of adjuvant CIK therapy using both an extended follow-up of the original RCT and a retrospective cohort study. An extended follow-up analysis of the RCT included 226 patients (114 in the CIK group and 112 in the control group). The follow-up duration was extended from 2 to 9 years after the enrollment of the last patient. In parallel, a retrospective RWD study was performed involving 577 patients from two tertiary centers in Korea, including 251 who received adjuvant CIK therapy and 326 controls. Propensity score matching (PSM) was applied to adjust for baseline imbalances. The primary endpoint was RFS in both studies. RESULTS: In the RWD study (median follow-up = 57.2 months), the CIK group demonstrated significantly prolonged RFS than controls both before PSM (median = 101.2 versus 64.7 months; HR = 0.69, 95% CI 0.53-0.90, P = 0.006) and after PSM (median = 101.2 vs. 65.7 months; HR = 0.64, 95% CI 0.45-0.91, P = 0.01). In the extended follow-up of the RCT (median follow-up = 116.1 months), the CIK group exhibited significantly prolonged RFS (median = 44.0 vs. 30.0 months; hazard ratio [HR] = 0.72, 95% confidence interval [CI] 0.54-0.97, P = 0.033) compared to the control group. CONCLUSIONS: Adjuvant CIK cell therapy significantly improved RFS in both a RWD study and a 9-year extended RCT follow-up, supporting its reproducible benefit in reducing recurrence after curative treatment of HCC. These consistent findings provide strong evidence for the clinical utility of CIK therapy as a durable adjuvant immunotherapeutic strategy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Republic of Korea.
- Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Hepatobiliopancreas and Transplant Surgery, Korea University Ansan Hospital, Ansan, Republic of Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Zitieren
APA
Shin, H., Park, Y., Song, B. G., Choi, W. M., Han, H. J., Lee, Y., Song, T. J., Yeon, J. E., Lim, Y. S., Hur, M. H., Lee, Y. B., Cho, E. J., Yu, S. J., Kim, Y. J., Lee, J. H., Yoon, J. H., & Lee, J. H. (2026). Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04301-6
Vancouver
Shin H, Park Y, Song BG, Choi WM, Han HJ, Lee Y, et al. Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04301-6
BibTeX
@article{Shin2026,
author = {Shin, Hyunjae and Park, Youngsu and Song, Byeong Geun and Choi, Won-Mook and Han, Hyung Joon and Lee, Youngwoo and Song, Tae-Jin and Yeon, Jong-Eun and Lim, Young-Suk and Hur, Moon Haeng and Lee, Yun Bin and Cho, Eun Ju and Yu, Su Jong and Kim, Yoon Jun and Lee, Joon Hyeok and Yoon, Jung-Hwan and Lee, Jeong-Hoon},
title = {Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04301-6}
}
EUVIMED